10-Q: CytoSorbents Reports Q3 2024 Results: Revenue Up, Losses Narrow Amidst Strategic Shifts

Sentiment:

Quarterly Report 7 November 2024 4:33 PM

CytoSorbents Corporation saw a revenue increase in Q3 2024, while also experiencing a reduction in net losses compared to the same period last year.

Capital raiseThe company is evaluating various traditional and alternative sources of capital, including additional less or non-dilutive debt financing, royalty financing, strategic or direct investments, equity financing, and/or combinations thereof.The company may need to raise additional capital if milestones related to the Avenue Capital Group debt facility are not achieved.

Better than expectedThe company's net loss significantly improved in Q3 2024 compared to Q3 2023, indicating better than expected financial performance.The company's revenue increased by 7% in Q3 2024 compared to Q3 2023, indicating better than expected sales performance.The company's research and development expenses decreased by 51% in Q3 2024 compared to Q3 2023, indicating better than expected cost management.

Summary

CytoSorbents Corporation reported a total revenue of $9.39 million for the third quarter of 2024, a 7% increase compared to $8.81 million in Q3 2023.
Product sales rose by 11% to $8.61 million, driven by a 21% increase in direct sales, while distributor sales decreased by 1%.
Grant income decreased by 26% to $777,000 due to the completion of several grants in 2023.
Gross profit decreased to $5.28 million from $5.61 million due to a planned production slowdown and a short-term manufacturing issue.
Research and development expenses significantly decreased by 51% to $1.85 million, primarily due to the completion of the STAR-T clinical trial.
The company's net loss for the quarter was $2.33 million, a significant improvement compared to a net loss of $9.19 million in the same quarter of the previous year.
For the nine months ended September 30, 2024, total revenue was $29.07 million, a 5% increase from $27.68 million in the same period of 2023.
The net loss for the nine-month period was $12.84 million, compared to a net loss of $22.67 million for the same period in 2023.
The company's cash, cash equivalents, and restricted cash totaled $12.2 million as of September 30, 2024, with $5.7 million in unrestricted cash.

Sentiment

Score: 6

Explanation: The document shows a mixed picture. While there are positive signs like revenue growth and reduced losses, the company's going concern status and need for additional capital raise concerns. The successful regulatory submissions are a positive, but the overall sentiment is cautiously optimistic.

Positives

The company experienced a 7% increase in total revenue for the third quarter of 2024.
Direct sales increased by 21% in Q3 2024, indicating strong market demand.
The net loss decreased significantly, showing improved financial performance.
Research and development expenses were reduced by 51%, primarily due to the completion of the STAR-T clinical trial.
The company secured a $20 million term-loan facility, strengthening its financial position.
The FDA accepted the De Novo application for DrugSorb-ATR, a key regulatory milestone.
The company obtained MDSAP certification and submitted its MDL application to Health Canada, expanding its regulatory reach.

Negatives

Grant income decreased by 26% in Q3 2024 due to the completion of several grants in 2023.
Gross profit decreased due to a planned production slowdown and a short-term manufacturing issue.
The company's unrestricted cash is not expected to fund operations beyond the next twelve months, raising concerns about its ability to continue as a going concern.
The company has a history of operating losses and an accumulated deficit of approximately $295.34 million.

Risks

The company's unrestricted cash is not expected to fund operations beyond the next twelve months, raising substantial doubt about its ability to continue as a going concern.
The company may need to raise additional capital if milestones related to the Avenue Capital Group debt facility are not achieved.
The company faces risks related to the outcome of ongoing litigation.
The company is subject to risks related to the current inflationary environment, which has increased labor and raw material costs.
The company's future success depends on the successful commercialization of its products, including DrugSorb-ATR, which is not yet approved in the United States or Canada.

Future Outlook

The company is focused on achieving milestones related to its Avenue Capital Group debt facility, which could increase its unrestricted cash position by up to $10 million. The company is also evaluating other sources of capital, including debt financing, royalty financing, strategic investments, and equity financing. The company is also focused on the regulatory approval of DrugSorb-ATR in the US and Canada.

Management Comments

Management believes that the company's cost-cutting efforts and potential cash infusions are sufficient to fund operations through 2025.
Management is actively pursuing additional milestones related to the Avenue Capital Group debt facility to increase unrestricted cash.
Management is evaluating various traditional and alternative sources of capital to support ongoing operations.

Industry Context

The company operates in the blood purification market, which is driven by the need for effective treatments for life-threatening conditions in intensive care and cardiac surgery. The company's focus on removing blood thinners and inflammatory agents aligns with the growing demand for innovative solutions in these areas. The company's progress with DrugSorb-ATR and its regulatory submissions positions it to compete in the market for antithrombotic removal systems.

Comparison to Industry Standards

CytoSorbents' revenue growth of 7% in Q3 2024 is a positive sign, but it is important to compare this to the growth rates of other medical device companies in the blood purification space. Companies like Baxter International and Fresenius Medical Care, which have a broader portfolio of products, may have different growth trajectories.
The company's gross margin of 61% in Q3 2024 is lower than the 72% in Q3 2023, indicating a need to improve manufacturing efficiency and cost management. Companies with established manufacturing processes and supply chains often have higher gross margins.
The reduction in R&D expenses by 51% is significant, but it is important to assess whether this reduction will impact the company's ability to develop new products and maintain its competitive edge. Companies in the medical device industry typically invest heavily in R&D to stay ahead of the competition.
The company's net loss of $2.33 million in Q3 2024 is an improvement compared to the $9.19 million loss in Q3 2023, but it is still important to monitor the company's path to profitability. Many medical device companies, especially those in the development stage, may experience losses for several years before achieving profitability.
The company's reliance on debt financing, as evidenced by the $20 million term-loan facility with Avenue Capital Group, is a common strategy for companies in the medical device industry. However, it is important to assess the company's ability to service this debt and its impact on the company's financial stability.
The company's regulatory submissions for DrugSorb-ATR are a key milestone, but it is important to compare the timelines and success rates of other companies in obtaining regulatory approvals for similar devices. Companies like Haemonetics and Terumo BCT, which have a long history of regulatory approvals, may have different timelines and success rates.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Chief Financial Officer	NA	Peter J. Mariani	August 14, 2024	New appointment

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Amendment to Long-Term Incentive Plan	The company amended its Amended and Restated 2014 Long-Term Incentive Plan to increase the total number of shares of common stock that may be issued or transferred under the Plan by 7,500,000 shares.	April 19, 2024	This change increases the number of shares available for employee and director compensation, which may impact the company's future dilution and compensation expenses.

Legal Proceedings

On March 5, 2024, Danielle Greene, a former employee, filed a complaint against the company alleging breach of the New Jersey Conscientious Employee Protection Act (CEPA).
The company intends to vigorously defend against the allegations.

Stakeholder Impact

Shareholders may be impacted by the company's need to raise additional capital and the potential dilution of their ownership.
Employees may be impacted by the company's cost-cutting efforts and headcount reductions.
Customers may benefit from the company's continued development of innovative blood purification technologies.
Creditors may be impacted by the company's debt financing and its ability to service its debt obligations.
Suppliers may be impacted by the company's cost-cutting efforts and its ability to pay for goods and services.

Next Steps

The company will continue to pursue milestones related to the Avenue Capital Group debt facility.
The company will continue to evaluate other sources of capital.
The company will focus on the regulatory approval of DrugSorb-ATR in the US and Canada.
The company will continue to manage its resources proactively and maintain tight control over expenditures.

Key Dates

Date	Description
April 12, 2019	Effective date of the Amended and Restated 2014 Long-Term Incentive Plan.
June 1, 2021	Commencement date of the lease for the new operating facility at 305 College Road East, Princeton, New Jersey.
July 14, 2021	Company filed a registration statement on Form S-3 with the SEC.
July 27, 2021	The 2021 Shelf registration statement was declared effective by the SEC.
December 30, 2021	Company entered into an Open Market Sale Agreement with Jefferies LLC.
August 10, 2022	Certain named executive officers and senior managers were granted 288,500 restricted stock units.
December 13, 2023	Closing date of the company's offering and issuance of warrants.
March 5, 2024	Danielle Greene, a former employee, filed a complaint against the company.
March 14, 2024	The company's Annual Report on Form 10-K for the year ended December 31, 2023 was filed with the SEC.
March 29, 2024	The company granted options to purchase 380,480 shares of common stock to certain executive officers and certain other non-executive officer employees related to the company's salary reduction for stock options program.
April 2, 2024	The company granted options to purchase 1,214,400 shares of common stock to the company's employees which will be awarded based upon each employee's 2024 individual performance evaluation.
April 2, 2024	The company granted options to purchase 922,147 shares of common stock to certain of the company's employees.
April 2, 2024	The company granted options to purchase 110,000 shares of common stock to members of the company's Board of Directors.
April 2, 2024	The company granted options to purchase 556,000 shares of common stock to certain senior managers of the company.
April 2, 2024	The Board of Directors granted 343,000 restricted stock units to certain senior managers of the company.
April 8, 2024	The company granted options to purchase 131,339 shares of common stock employees related to the company's salary reduction for stock options program.
April 19, 2024	Amendment No. 2024-1 to CytoSorbents Corporation Amended and Restated 2014 Long-Term Incentive Compensation Plan.
June 6, 2024	Stockholders approved an additional 7,500,000 shares for the long-term incentive plan.
June 28, 2024	Closing date of the Loan and Security Agreement with Avenue Capital Group and payoff of Bridge Bank debt.
June 28, 2024	The company issued 1,645,569 warrants in connection with the closing of the Loan and Security Agreement with Avenue Capital Group.
July 26, 2024	The Company filed a registration statement on Form S-3 with the SEC (the 2024 Shelf).
August 6, 2024	The company's license agreement with Purolite expired.
August 14, 2024	The company granted options to purchase 80,000 shares of common stock in connection with the appointment of its new Chief Financial Officer.
August 14, 2024	The company granted options to purchase 215,000 shares of common stock that will vest only upon the achievement of certain milestones pursuant to the terms of the company's existing 2022 2025 performance pool in place for the company's management team.
August 14, 2024	The company granted 65,000 restricted stock units in connection with the appointment of its new Chief Financial Officer.
September 26, 2024	The Company filed Amendment No. 1 to the Form S-3 with the SEC.
September 27, 2024	The Company submitted the DrugSorb-ATR medical device De Novo marketing application to the FDA.
September 30, 2024	The 2024 Shelf was declared effective by the SEC.
September 30, 2024	End of the reporting period for the Q3 2024 results.
October 22, 2024	The company announced the FDA acceptance of the DrugSorb-ATR marketing submission.
November 1, 2024	The company received its Medical Device Single Audit Program (MDSAP) certification and submitted its Medical Device License (MDL) application to Health Canada.
November 7, 2024	Date of the filing of the Q3 2024 report.

Keywords

CytoSorb, DrugSorb-ATR, blood purification, medical devices, FDA, clinical trials, revenue, net loss, research and development, debt financing, regulatory approval

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.